CORE 4 - SUMMARY COVID-19 remains a worldwide health threat. While some people recover quickly and have mild/no symptoms, at least one third develop long-term symptoms referred to as Long-COVID. In order to identify new therapeutic targets this Program will decipher the role of specific pathways and identify the cell-types that control inflammation and virus virulence. The “Cell Derivation and Maintenance Core” or Core 4 will support this Program by providing primary human and/or mouse airway epithelial cells, immune cells, endothelial cells, and cells isolated from the brain. This core will also provide blood as well as fixed brain and lung tissues from patients non-infected and infected with SARS-CoV-2. This core will support Projects 1-3 and will also provide primary airway cells to Core 3.